Literature DB >> 25681574

Inhibition of LINGO-1 promotes functional recovery after experimental spinal cord demyelination.

Yongjie Zhang1, Yi Ping Zhang2, Blake Pepinsky3, Guanrong Huang4, Lisa B E Shields5, Christopher B Shields6, Sha Mi7.   

Abstract

Blocking LINGO-1 has been shown to enhance remyelination in the rat lysolecithin-induced focal spinal cord demyelination model. We used transcranial magnetic motor-evoked potentials (tcMMEPs) to assess the effect of blocking LINGO-1 on recovery of axonal function in a mouse lysolecithin model at 1, 2 and 4weeks after injury. The role of LINGO-1 was assessed using LINGO-1 knockout (KO) mice and in wild-type mice after intraperitoneal administration of anti-LINGO-1 antagonist monoclonal antibody (mAb3B5). Response rates (at 2 and 4weeks) and amplitudes (at 4weeks) were significantly increased in LINGO-1 KO and mAb3B5-treated mice compared with matched controls. The latency of potentials at 4weeks was significantly shorter in mAb3B5-treated mice compared with controls. Lesion areas in LINGO-1 KO and mAb3B5-treated mice were reduced significantly compared with matched controls. The number of remyelinated axons within the lesions was increased and the G-ratios of the axons were decreased in both LINGO-1 KO and mAb3B5-treated mice compared with matched controls. These data provide morphometric and functional evidence of enhancement of remyelination associated with antagonism of LINGO-1.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Demyelination; Electrophysiology; LINGO-1; Lysolecithin model; Morphometry; Multiple sclerosis; tcMMEP

Mesh:

Substances:

Year:  2015        PMID: 25681574     DOI: 10.1016/j.expneurol.2015.02.006

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  15 in total

Review 1.  Oligodendrocyte regeneration: Its significance in myelin replacement and neuroprotection in multiple sclerosis.

Authors:  Kelly A Chamberlain; Sonia E Nanescu; Konstantina Psachoulia; Jeffrey K Huang
Journal:  Neuropharmacology       Date:  2015-10-22       Impact factor: 5.250

Review 2.  Microenvironmental regulation of oligodendrocyte replacement and remyelination in spinal cord injury.

Authors:  Arsalan Alizadeh; Soheila Karimi-Abdolrezaee
Journal:  J Physiol       Date:  2016-03-29       Impact factor: 5.182

Review 3.  Manipulating oligodendrocyte intrinsic regeneration mechanism to promote remyelination.

Authors:  Fabien Binamé; Lucas D Pham-Van; Dominique Bagnard
Journal:  Cell Mol Life Sci       Date:  2021-05-21       Impact factor: 9.261

Review 4.  Remyelinating Pharmacotherapies in Multiple Sclerosis.

Authors:  Riley M Bove; Ari J Green
Journal:  Neurotherapeutics       Date:  2017-10       Impact factor: 7.620

Review 5.  Extracellular cues influencing oligodendrocyte differentiation and (re)myelination.

Authors:  Natalie A Wheeler; Babette Fuss
Journal:  Exp Neurol       Date:  2016-03-23       Impact factor: 5.330

Review 6.  Emerging therapies to target CNS pathophysiology in multiple sclerosis.

Authors:  Jiwon Oh; Amit Bar-Or
Journal:  Nat Rev Neurol       Date:  2022-06-13       Impact factor: 44.711

Review 7.  Nudging oligodendrocyte intrinsic signaling to remyelinate and repair: Estrogen receptor ligand effects.

Authors:  Anna J Khalaj; Jonathan Hasselmann; Catherine Augello; Spencer Moore; Seema K Tiwari-Woodruff
Journal:  J Steroid Biochem Mol Biol       Date:  2016-01-14       Impact factor: 4.292

Review 8.  Therapeutic Advances and Challenges in the Treatment of Progressive Multiple Sclerosis.

Authors:  Laura E Baldassari; Robert J Fox
Journal:  Drugs       Date:  2018-10       Impact factor: 11.431

Review 9.  Biomaterial Approaches to Enhancing Neurorestoration after Spinal Cord Injury: Strategies for Overcoming Inherent Biological Obstacles.

Authors:  Justin R Siebert; Amber M Eade; Donna J Osterhout
Journal:  Biomed Res Int       Date:  2015-09-27       Impact factor: 3.411

10.  Clobetasol promotes remyelination in a mouse model of neuromyelitis optica.

Authors:  Xiaoming Yao; Tao Su; A S Verkman
Journal:  Acta Neuropathol Commun       Date:  2016-04-26       Impact factor: 7.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.